Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $49.47 USD
Change Today -0.29 / -0.58%
Volume 945.1K
SNY On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008

France

Phone: 33 1 53 77 40 00

Fax: 33 1 53 77 42 96

cer cells from dividing, which results in destroying various cancer cells. Taxotere is available in approximately 90 countries as an injectable solution. It has been approved for use in 11 indications in 5 different tumor types (breast, prostate, gastric, lung, and head and neck). Taxotere is indicated for early stage and metastatic breast cancer, first-line and second-line metastatic non-small cell lung cancer, androgen-independent (hormone-refractory) metastatic prostate cancer, advanced gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction), and the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. The top four countries contributing to sales of Taxotere were Japan, China, Taiwan, and South Korea in 2014. Generics of docetaxel were launched in Europe, the United States, and Japan. Eloxatin: Eloxatin (oxaliplatin) is a platinum-based cytotoxic agent. Eloxatin, in combination with infusional administration of two other chemotherapy drugs, 5-fluorouracil/leucovorin (the FOLFOX regimen), is approved by the FDA for adjuvant treatment of people with stage III colon cancer who have had their primary tumors surgically removed. Eloxatin is in-licensed from Debiopharm and is marketed in approximately 70 countries worldwide. The major three countries contributing to sales of Eloxatin were Canada, China, and the United States in 2014. Thymoglobulin: Thymoglobulin (Anti-thymocyte Globulin) is a polyclonal anti-human thymocyte antibody preparation that acts as an immuno-suppressive and immuno-modulating agent. The product's primary mechanism of action is T-cell depletion, which is complemented by a host of other immuno-modulating effects. Thymoglobulin is marketed in approximately 65 countries. Depending on the country, Thymoglobulin is indicated for the treatment and/or prevention of acute rejection in organ transplantation, immunosuppressive therapy in aplastic anemia, and/or the treatment and/or prevention of Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation. The major countries contributing to Thymoglobulin sales were the United States, China, France, and Japan in 2014. Mozobil: Mozobil (plerixafor injection) is a hematopoietic stem cell mobilizer indicated in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The major countries contributing to Mozobil sales were the United States, Germany, the U.K., and France in 2014. Zaltrap: Zaltrap (aflibercept) is a recombinant fusion protein, which acts as a soluble decoy receptor that binds to Vascular Endothelial Growth Factor-A (VEGF-A), VEGF-B and placental growth factor, preventing the bound VEGF from binding to their native receptors. In the United States, Zaltrap is approved under the U.S. proper name ziv-aflibercept for use in combination with FOLFIRI, in patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. Zaltrap is marketed in the United States. In the European Union, Zaltrap was approved in 2013 by the European Commission to treat metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. Zaltrap was approved in a further 18 countries in 2014, and is approved in approximately 50 countries worldwide. Marketing authorization applications are under review in various other countries. The major countries contributing to sales of Zaltrap were the United States, Germany, France, and the United Kingdom in 2014. Other Prescription Products Plavix/Iscover: Plavix (clopidogrel bisulfate), a platelet adenosine diphosphate (ADP) receptor antagonist with a rapid onset of action that selectively inhibits platelet aggregation induced by ADP, is indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, recent ischemic stroke or established peripheral arterial disease. Plavix is indicated for the treatment o

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNY:US $49.47 USD -0.29

SNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.21 USD -0.30
Amgen Inc $153.26 USD -1.73
Bayer AG €126.31 EUR -0.59
Bristol-Myers Squibb Co $67.48 USD -0.19
Novo Nordisk A/S kr368.70 DKK -2.20
View Industry Companies
 

Industry Analysis

SNY

Industry Average

Valuation SNY Industry Range
Price/Earnings 28.0x
Price/Sales 3.4x
Price/Book 2.1x
Price/Cash Flow 17.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.